Biomedical subjects

Pierre Soubeyran

Publications and source records attributed to Pierre Soubeyran.

3 recordsLinked to original sources

PubMed2002

[Lymphomas in the elderly].

About 50% of lymphomas occur in patients older than 60 and this proportion will probably increase in the future because of increasing lymphoma incidence and population ageing in developed countries. Most of the characteristics of lymphomas occurring in the elderly do not differ from that of their younger counterpart and standard treatment should be applied whenever possible. However, a significant proportion of these patients, which remains difficult to detect, is exposed to a high risk of toxicity. Further studies should lead to better designate this population. Among possible tools, comprehensive geriatric assessment can be valuable although it remains necessary to adapt it to the oncohematology context.

Age Factors↗

PubMed2002

Quality of life in patients with aggressive non-Hodgkin's lymphoma. Validation of the medical outcomes study short form 20 and the Rotterdam symptom checklist in older patients.

In the elderly population, cancer treatment aims to cure and/or maintain Quality of Life (QoL). However, there is little QoL data to provide evidence for QoL benefits for some of the cancer treatments. This pilot study developed valid QoL questionnaires in French, for patients over 65 years with a diagnosis of large cell lymphoma, part of the Lymâge phase II study. They were asked to complete two questionnaires, the Medical Outcomes Study Short Form 20 (MOS SF20; generic) and the Rotterdam symptom checklist (RSCL; cancer-specific). Between June 1995 and April 1997, questionnaires were returned by 63 of 89 patients. This article reports the process undertaken to adapt the English version to a French setting, and provides the results of factor analysis, convergent and discriminant validity and reliability. Our data suggest that QoL questionnaires can be used in elderly patients. These two questionnaires are validated in French and would help us to analyse the QoL of elderly patients with the development of new treatments as done in the Lymâge study.

Aged↗

PubMed2002

[Update on lymphomas].

Important progress have been recently achieved in the management of Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). Prognostic factors are now better defined in HD thanks to new biologic and radiologic information which complete old and relevant clinical factors. These parameters are expected to improve decision making in patient's management. However, treatment strategy is under new discussion and controversies about the role of radiotherapy and its doses. There are now enough arguments to consider radiotherapy unnecessary in advanced stages when a complete remission is achieved by chemotherapy. There is also important concern about late effects of treatment and not only secondary cancers. Non-Hodgkin's lymphomas are heterogeneous and different entities are now better defined and described, thanks to a common and similar language for immunological clinical data and treatment outcome. New strategies are under investigation using monoclonal antibodies with or without radioisotopes, in association with chemotherapy or radiotherapy. Undoubtedly, these new approaches are going to improve the overall prognosis of NHL.

Hematopoietic Stem Cell Transplantation↗